Letters to the Editor
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impactAuthor links open overlay panel,
,
,
,
,
Highlights
- •
Baricitinib at 4 mg/day/orally was given to 12 patients with moderate COVID-19.
- •
In baricitinib-treated patients no adverse events were recorded, after 2 weeks.
- •
Clinical and respiratory parameters significantly improved at 2 weeks.
- •
None of the baricitinib-treated patients required admission to ICU.
- •
Proper control group was missing; this is required to demonstrate the efficacy.
View Abstract© 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.